This company listing is no longer active
Eden Empire Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Eden Empire's earnings have been declining at an average annual rate of -2%, while the Pharmaceuticals industry saw earnings growing at 19.4% annually. Revenues have been growing at an average rate of 197.5% per year.
Información clave
-2.0%
Tasa de crecimiento de los beneficios
15.8%
Tasa de crecimiento del BPA
| Crecimiento de la industria Pharmaceuticals | 7.3% |
| Tasa de crecimiento de los ingresos | 197.5% |
| Rentabilidad financiera | n/a |
| Margen neto | -1,716.9% |
| Última actualización de beneficios | 30 Apr 2022 |
Actualizaciones de resultados anteriores recientes
No hay actualizaciones
Recent updates
Desglose de ingresos y gastos
Cómo gana y gasta dinero Eden Empire. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 30 Apr 22 | 0 | -5 | 2 | 0 |
| 31 Jan 22 | 0 | -5 | 2 | 0 |
| 31 Oct 21 | 0 | -4 | 2 | 0 |
| 31 Jul 21 | 0 | -4 | 2 | 0 |
| 30 Apr 21 | 0 | -5 | 3 | 0 |
| 31 Jan 21 | 0 | -4 | 2 | 0 |
| 31 Oct 20 | 0 | -4 | 2 | 0 |
| 31 Jul 20 | 0 | -5 | 3 | 0 |
| 30 Apr 20 | 0 | -3 | 3 | 0 |
Ingresos de calidad: GA1B is currently unprofitable.
Margen de beneficios creciente: GA1B is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: Insufficient data to determine if GA1B's year-on-year earnings growth rate was positive over the past 5 years.
Acelerando crecimiento: Unable to compare GA1B's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: GA1B is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (9.4%).
Rentabilidad financiera
Alta ROE: GA1B's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.